source
- Ipsen to acquire Swiss biotech Memo Therapeutics in up to €800 million deal for BK virus drugIpsen announced it will purchase Memo Therapeutics, a Swiss biotech, in a transaction valued at up to about €800 million. The agreement provides Memo investors with €200 million upfront and potent…
- Abivax shares jump 40% after Phase 3 data show no excess cancer risk for ulcerative colitis drugAbivax reported new safety data from its Phase 3 trial of obefazimod in ulcerative colitis. The data indicated malignancy rates among trial participants were comparable to background rates observed…